Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dihydrocucurbitacin B is a naturally occurring cucurbitane triterpenoid isolated from various plants of the Cucurbitaceae family, including *Cayaponia tayuya*, *Wilbrandia ebracteata*, and *Trichosanthes kirilowii*. It exhibits a wide range of pharmacological activities, including anti-inflammatory, immunosuppressive, lipid-lowering, and anticancer properties. Mechanistically, dihydrocucurbitacin B has been shown to selectively inhibit the nuclear factor of activated T cells (NFAT) in human lymphocytes and suppress cyclooxygenase-2 (COX-2) activity. In lipid metabolism, it promotes LDL clearance by upregulating low-density lipoprotein receptor (LDLR) expression and downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9) expression. In oncology models, it induces G2/M cell-cycle arrest and apoptosis, potentially through the downregulation of the PI3K/Akt/mTOR signaling pathway and cyclins such as cyclin B1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dihydrocucurbitacin b.